




PHARMACEUTICAL 2018

Neurotrophe Inc.
Rank 129 of 342





PHARMACEUTICAL 2018

Neurotrope Inc.
Rank 129 of 342

The relative strengths and weaknesses of Neurotrope Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neurotrope Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 122% points. The greatest weakness of Neurotrope Inc. is the variable Net Income, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is 144%, being 99% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	16,424
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,558
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	2,697
Other Liabilities	0
Other Net Income	87
Other Revenues	0
Property and Equipment	21
Research and Development	4,549
Selling, General and Administrative Expense	5,456

Output Variable	Value in 1000 USD
Assets	16,444
Liabilities	1,558
Expenses	12,702
Revenues	0
Stockholders Equity	14,886
Net Income	-12,615
Comprehensive Net Income	-12,615
Economic Capital Ratio	144%